Natural and synthetic PPARγ agonists have shown potential in the treatment of various liver diseases, including non‐alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, liver fibrosis and hepatocellular carcinoma.54, 55. The gene discussed is PPARG; the disease is Hepatic fibrosis.